IBDEI2CF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39354,1,4,0)
 ;;=4^M48.36
 ;;^UTILITY(U,$J,358.3,39354,2)
 ;;=^5012120
 ;;^UTILITY(U,$J,358.3,39355,0)
 ;;=M48.37^^183^2018^58
 ;;^UTILITY(U,$J,358.3,39355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39355,1,3,0)
 ;;=3^Traumatic spondylopathy, lumbosacral region
 ;;^UTILITY(U,$J,358.3,39355,1,4,0)
 ;;=4^M48.37
 ;;^UTILITY(U,$J,358.3,39355,2)
 ;;=^5012121
 ;;^UTILITY(U,$J,358.3,39356,0)
 ;;=M48.31^^183^2018^59
 ;;^UTILITY(U,$J,358.3,39356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39356,1,3,0)
 ;;=3^Traumatic spondylopathy, occipito-atlanto-axial region
 ;;^UTILITY(U,$J,358.3,39356,1,4,0)
 ;;=4^M48.31
 ;;^UTILITY(U,$J,358.3,39356,2)
 ;;=^5012115
 ;;^UTILITY(U,$J,358.3,39357,0)
 ;;=M48.38^^183^2018^60
 ;;^UTILITY(U,$J,358.3,39357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39357,1,3,0)
 ;;=3^Traumatic spondylopathy, sacral and sacrococcygeal region
 ;;^UTILITY(U,$J,358.3,39357,1,4,0)
 ;;=4^M48.38
 ;;^UTILITY(U,$J,358.3,39357,2)
 ;;=^5012122
 ;;^UTILITY(U,$J,358.3,39358,0)
 ;;=M48.35^^183^2018^62
 ;;^UTILITY(U,$J,358.3,39358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39358,1,3,0)
 ;;=3^Traumatic spondylopathy, thoracolumbar region
 ;;^UTILITY(U,$J,358.3,39358,1,4,0)
 ;;=4^M48.35
 ;;^UTILITY(U,$J,358.3,39358,2)
 ;;=^5012119
 ;;^UTILITY(U,$J,358.3,39359,0)
 ;;=M48.33^^183^2018^56
 ;;^UTILITY(U,$J,358.3,39359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39359,1,3,0)
 ;;=3^Traumatic spondylopathy, cervicothoracic region
 ;;^UTILITY(U,$J,358.3,39359,1,4,0)
 ;;=4^M48.33
 ;;^UTILITY(U,$J,358.3,39359,2)
 ;;=^5012117
 ;;^UTILITY(U,$J,358.3,39360,0)
 ;;=M48.34^^183^2018^61
 ;;^UTILITY(U,$J,358.3,39360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39360,1,3,0)
 ;;=3^Traumatic spondylopathy, thoracic region
 ;;^UTILITY(U,$J,358.3,39360,1,4,0)
 ;;=4^M48.34
 ;;^UTILITY(U,$J,358.3,39360,2)
 ;;=^5012118
 ;;^UTILITY(U,$J,358.3,39361,0)
 ;;=R47.01^^183^2019^1
 ;;^UTILITY(U,$J,358.3,39361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39361,1,3,0)
 ;;=3^Aphasia
 ;;^UTILITY(U,$J,358.3,39361,1,4,0)
 ;;=4^R47.01
 ;;^UTILITY(U,$J,358.3,39361,2)
 ;;=^5019488
 ;;^UTILITY(U,$J,358.3,39362,0)
 ;;=I69.920^^183^2019^2
 ;;^UTILITY(U,$J,358.3,39362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39362,1,3,0)
 ;;=3^Aphasia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,39362,1,4,0)
 ;;=4^I69.920
 ;;^UTILITY(U,$J,358.3,39362,2)
 ;;=^5007553
 ;;^UTILITY(U,$J,358.3,39363,0)
 ;;=I69.91^^183^2019^3
 ;;^UTILITY(U,$J,358.3,39363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39363,1,3,0)
 ;;=3^Cognitive deficits following unsp cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,39363,1,4,0)
 ;;=4^I69.91
 ;;^UTILITY(U,$J,358.3,39363,2)
 ;;=^5007552
 ;;^UTILITY(U,$J,358.3,39364,0)
 ;;=I69.991^^183^2019^5
 ;;^UTILITY(U,$J,358.3,39364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39364,1,3,0)
 ;;=3^Dysphagia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,39364,1,4,0)
 ;;=4^I69.991
 ;;^UTILITY(U,$J,358.3,39364,2)
 ;;=^5007569
 ;;^UTILITY(U,$J,358.3,39365,0)
 ;;=G11.1^^183^2019^6
 ;;^UTILITY(U,$J,358.3,39365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39365,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,39365,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,39365,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,39366,0)
 ;;=I69.952^^183^2019^11
 ;;^UTILITY(U,$J,358.3,39366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39366,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left dominant side
 ;;^UTILITY(U,$J,358.3,39366,1,4,0)
 ;;=4^I69.952
 ;;^UTILITY(U,$J,358.3,39366,2)
 ;;=^5133586
